Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Targeted Oncology"
DOI: 10.1007/s11523-018-0600-3
Abstract: BackgroundSarcopenia is a state of degenerative skeletal muscle wasting induced by cancer cachexia.ObjectiveTo evaluate the prognostic impact of changes in skeletal muscle mass (SMM) during first-line sunitinib therapy on oncological outcomes in metastatic renal cell… read more here.
Keywords: first line; skeletal muscle; sunitinib therapy;
Sunitinib therapy for imatinib-resistant and/or intolerant gastrointestinal stromal tumors: comparison of safety and efficacy between standard and reduced dosage regimens.
Sign Up to like & getrecommendations! Published in 2023 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyac202
Abstract: BACKGROUND Sunitinib therapy for patients with imatinib-resistant and/or intolerant gastrointestinal stromal tumors (GISTs) often causes severe adverse events (AEs) that lead to treatment discontinuation. METHODS We retrospectively reviewed the clinical records of imatinib-resistant and/or intolerant… read more here.
Keywords: dosage; reduced dosage; dosage group; sunitinib therapy ... See more keywords
Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female
Sign Up to like & getrecommendations! Published in 2018 at "World Journal of Surgical Oncology"
DOI: 10.1186/s12957-018-1328-3
Abstract: BackgroundSunitinib is a multiple receptor tyrosine kinase inhibitor (TKI) used for the treatment of renal cell carcinoma (RCC). It increases the median survival considerably with minimum side effects. Alopecia is one of the rare side effects.… read more here.
Keywords: cell carcinoma; progression; sunitinib therapy;